Kestra Medical Technologies, Ltd. (KMTS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Strength Seen in Kestra Medical Technologies, Ltd. (KMTS): Can Its 8.1% Jump Turn into More Strength?
Kestra Medical Technologies, Ltd. (KMTS) saw its shares surge in the last session with trading volume being higher than average.
Kestra Medical Technologies, Ltd. (KMTS) Q4 2026 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Q4 2026 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Reports Q4 Loss, Tops Revenue Estimates
Kestra Medical Technologies, Ltd. (KMTS) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.59.
Kestra Medical Technologies Q4 Earnings Call Highlights
Kestra Medical Technologies NASDAQ: KMTS reported a sharp increase in fourth-quarter revenue and issued fiscal 2027 guidance calling for continued growth, as executives said demand for the company's ASSURE wearable cardioverter defibrillator system is being driven by new accounts, deeper penetration of existing customers and expansion of its commercial team.
Kestra Medical Technologies, Ltd. (KMTS) Q3 2026 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Q3 2026 Earnings Call Transcript
KMTS, Biobeat Partner to Expand Diagnostic Insight in Cardiac Recovery
Kestra teams up with Biobeat in an exclusive deal, investing $5M to add continuous blood pressure monitoring to the ASSURE WCD during cardiac recovery.
Kestra Medical Technologies, Ltd. (KMTS) Presents at 44th Annual J.P.
Kestra Medical Technologies, Ltd. (KMTS) Presents at 44th Annual J.P.
Kestra Medical Technologies, Ltd. (KMTS) Q2 2026 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Q2 2026 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Q1 2026 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS ) Q1 2026 Earnings Call September 11, 2025 4:30 PM EDT Company Participants Neil Bhalodkar - Vice President of Investor Relations Brian Webster - Founder, President, CEO & Director Vaseem Mahboob - Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Michael Polark - Wolfe Research, LLC Presentation Operator Good afternoon, and welcome to the Kestra Medical Technologies Earnings Conference Call.
Kestra Medical: Skipping A Heartbeat
Kestra Medical Technologies, Ltd. shows strong sales growth but faces significant operating losses and a concerning slowdown in sequential revenue growth. Despite a large addressable market and innovative cardiac device, the company's one-product focus and high valuation amplify risks. Recent quarters reveal only modest revenue increases, casting doubt on the sustainability of Kestra's growth trajectory post-IPO.
Kestra Medical Technologies: A Potential Promising Public Offering
Kestra Medical Technologies has seen rapid growth but incurs substantial operating losses, making its valuation exercise a hard one. The company's Cardiac Recovery System, including the ASSURE WCD, addresses a significant market need for sudden cardiac arrest intervention. Despite strong product adoption and a large addressable market, risks include high losses, being a one-product business, and potential growth slowdown.
Kestra Medical Technologies aims to raise $150M in IPO
Kirkland, Wash.-based Kestra Medical Technologies is aiming to raise about $150 million in its initial public offering, pricing shares between $14 and $16 on the Nasdaq, according to a new regulatory filing.
